<DOC>
	<DOCNO>NCT01979419</DOCNO>
	<brief_summary>PRIMARY OBJECTIVES -Establish registry Alzheimer 's disease ( AD ) subcortical ischemic vascular dementia ( SIVD ) STUDY DESIGN -This non-randomized , natural history , observational , registry study . SAMPLE SIZE AND RECRUITMENT - Five hundred subject enrol clinical site ( 50 NC , 200 MCI , 50 AD , 100 vMCI , 100 SIVD ) SUMMARY OF KEY ELIGIBILITY CRITERIA - Newly enrol subject 50-80 ( inclusive ) year age . - 1 ) Cognitively Normal Subjects - 2 ) MCI subject - 3 ) AD subject - 4 ) vMCI SIVD PROCEDURES - Recruited subject clinical/cognitive assessment , biomarker genetic sample collection , image . - Subjects follow 36 month baseline visit . All assessment perform every year baseline ( 0 , 12 , 24 , 36 month ) , except ; 1 ) FDG-PET amyloid-PET perform every two year , i.e. , baseline 24 month visit . 2 ) CSF collection also perform baseline 24 month visit . 3 ) Clinical/cognitive assessment MRI evaluation additionally do 6 month baseline determine short term change . OUTCOME MEASURES - Group differences clinical , cognitive , biochemical , imaging measurement . - Rate conversion change disease severity evaluate among group - Correlations among biomarkers biomarker change</brief_summary>
	<brief_title>Korea Alzheimer 's Disease Neuroimaging Initiative</brief_title>
	<detailed_description>The major goal K-ADNI : 1 . Establish registry Alzheimer 's disease ( AD ) subcortical ischemic vascular dementia ( SIVD ) - Collect longitudinal clinical , image , genetic , biochemical biomarker data clinical neuroscience study 500 subject five diagnostic category : cognitively normal control ( NC ) , mild cognitive impairment ( MCI ) , mild AD , vascular MCI ( vMCI ) , SIVD . - The following measurement know representative parameter dementia progress include . 1 ) clinical characteristic , 2 ) neuropsychological test , 3 ) structural functional magnetic resonance image ( MRI ) , 4 ) Fludeoxyglucose ( FDG ) -positron emission tomography ( PET ) , 5 ) amyloid PET ( 18F-flutemetamol ) , 6 ) cerebrospinal fluid ( CSF ) blood sample , 7 ) genetic analysis . 2 . Determination factor crucial aggravation deterrence progress dementia syndrome , factor use predictor outcome measure AD SIVD - Determine relationship among clinical , image , genetic , biochemical biomarker characteristic entire spectrum AD , pathology evolves normal age mild symptom , MCI , finally dementia . - Also , determine relationship among clinical , image , genetic , biochemical biomarker characteristic vascular MCI ( vMCI ) SIVD , important sub-population dementia syndrome especially Asian population . 3 . Identification surrogate marker new drug development patient AD SIVD - Identify prognostic marker AD SIVD , identify outcome measure use clinical trial , help develop effective clinical trial scenario new drug . 4 . Development standard model acquire multi-site neuroimaging study data - Develop improve method lead uniform standard acquire longitudinal multi-site clinical , MRI , PET , biological marker ( blood , CSF , gene ) data patient AD , MCI , vMCI , SIVD , elderly control .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<mesh_term>Dementia , Vascular</mesh_term>
	<criteria>1 . Cognitively Normal Subjects MiniMental State Examination ( MMSE ) score 2430 ( inclusive ) Clinical Dementia Rating ( CDR ) =0 nondepressed ( Geriatric Depression Scale score less 4 ) evidence cognitive impairment 2 . MCI subject MMSE score 2430 ( inclusive ) subjective memory concern report subject , informant , clinician objective memory loss measure age education year adjust score logical memory subtest ( 1.5 SD ) CDR=0.5 preserve activity daily live , absence dementia . 3 . AD subject MMSE score 2026 ( inclusive ) CDR= 0.5 1.0. meet National Institute Neurological Communicative Disorders Stroke / Alzheimer 's Disease Related Disorders Associations ( NINCDS/ADRDA ) criteria probable AD 4. vMCI SIVD For diagnosis vMCI SIVD , necessary meet clinical/cognitive test score MCI AD . Presence vascularity determine ; 1 ) 2 vascular risk factor recent 5 year ( hypertension , diabetes , stroke , dyslipidemia , cardiovascular disease , obesity , lack exercise , smoking ) AND 2 ) 1 evidence vascular neurological symptom , sign , history AND 3 ) neuroimaging evidence white matter hyperintensity , rat moderate severe MR T2weighted image ( T2WI ) FLAIR image . Screening/baseline MRI scan evidence infection , infarction , focal lesion ; Participants multiple lacunes lacunes critical memory structure exclude Presence pacemaker , aneurysm clip , artificial heart valve , ear implant , metal fragment foreign object eye , skin body Major depression , bipolar disorder describe Diagnostic Statistical Manual Mental Disorders , Fourth Edition ( DSMIV ) within past 1 year Currently treat medication obsessivecompulsive disorder attention deficit disorder History schizophrenia History alcohol substance abuse dependence within past 2 year Any significant systemic illness unstable medical condition could lead difficulty comply protocol Any significant neurologic disease Parkinson 's disease , multiinfarct dementia , Huntington 's disease , normal pressure hydrocephalus , brain tumor , progressive supranuclear palsy , seizure disorder , subdural hematoma , multiple sclerosis , history significant head trauma follow persistent neurologic default know structural brain abnormality .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>mild cognitive impairment</keyword>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>subcortical Vascular Dementia</keyword>
	<keyword>amyloid</keyword>
	<keyword>plaque</keyword>
	<keyword>neuroimaging</keyword>
	<keyword>biomarkers</keyword>
	<keyword>cognition disorder</keyword>
	<keyword>early detection</keyword>
	<keyword>pre-dementia</keyword>
	<keyword>dementia</keyword>
	<keyword>vascular MCI</keyword>
</DOC>